September 15, 2011
CNS THERAPEUTICS NAMED PREMIER CONTRACTED SUPPLIER
CNS Therapeutics today announced that it has become a Premier Contracted Supplier, effective Sept. 15, 2011. The contract will make Gablofen® (baclofen injection) available to Premier's member healthcare organizations. Read more.
June 15, 2011
CNS THERAPEUTICS NAMED NOVATION AWARDED SUPPLIER
CNS Therapeutics today announced that it has become a Novation Awarded Supplier, effective June 15, 2011. The contract will make Gablofen® (baclofen injection) available to Novation's member healthcare organizations. Read more.
April 08, 2011
CNS THERAPEUTICS NAMES FORMER KPMG EXECUTIVE AS CFO
CNS Therapeutics today announced the appointment of Andy LaFrence as Chief Financial Officer. Andy replaces Scott Bronson, who remains with the company as Co-founder and Administrative and Compliance Officer. Read more.
March 28, 2011
FDA CLASSIFIES GABLOFEN® (baclofen injection)
AS AP-RATED GENERIC
CNS Therapeutics today announced that the FDA has officially classified Gablofen as an AP-rated therapeutic equivalent (TE) generic drug, with Lioresal as the reference listed drug (RLD). This means that Gablofen, for use in the management of severe spasticity, can be substituted for Lioresal with the full expectation that Gablofen will produce the same clinical effect and safety profile as Lioresal, a drug manufactured by Novartis and marketed exclusively by Medtronic. Read more.
November 23, 2010
FDA APPROVES MOVEMENT DISORDER DRUG FROM CNS THERAPEUTICS: GABLOFEN® (baclofen injection) FOR THE TREATMENT OF SEVERE SPASTICITY
Today, CNS Therapeutics announced the FDA approval of Gablofen® (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a new, easy-to-administer and cost-effective intrathecal baclofen treatment option. Severe spasticity is a movement disorder affecting more than 500,000 patients in the U.S. alone and is often brought on by multiple sclerosis, cerebral palsy, spinal cord injury, brain trauma and stroke. Read more.
Media Contacts
Melissa Zipin
Lois Paul & Partners
(781) 782-5726
melissa_zipin@lpp.com